Last reviewed · How we verify
LD Sing2016 M2SR H3N2 influenza vaccine — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
LD Sing2016 M2SR H3N2 influenza vaccine (LD Sing2016 M2SR H3N2 influenza vaccine) — FluGen Inc.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| LD Sing2016 M2SR H3N2 influenza vaccine TARGET | LD Sing2016 M2SR H3N2 influenza vaccine | FluGen Inc | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- LD Sing2016 M2SR H3N2 influenza vaccine CI watch — RSS
- LD Sing2016 M2SR H3N2 influenza vaccine CI watch — Atom
- LD Sing2016 M2SR H3N2 influenza vaccine CI watch — JSON
- LD Sing2016 M2SR H3N2 influenza vaccine alone — RSS
Cite this brief
Drug Landscape (2026). LD Sing2016 M2SR H3N2 influenza vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/ld-sing2016-m2sr-h3n2-influenza-vaccine. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab